Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Fourth Quarter of 2023
FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
FDA Roundup: December 15, 2023
Superior Energy Services Announces Expectation of Special Dividend
CorMedix Inc. Announces Appointment of Chief Legal Officer
INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
Research Provides Proof That Cellular RPM™ Is Easy To Use And Can Improve Outcomes
US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer
 7   8   9   10   11     12    13   14   15   16   17 
 <<   <   >   >>